

Clinical Article

The Effects of Propofol and Thiopental Continuous Infusion on Serum Potassium Disturbances in Neurosurgical Patients

Tae Kyong Kim, M.D.,¹ Young-Jin Lim, M.D.,¹ Jae-Woo Ju, M.D.,¹ Jin Wook Kim, M.D.,² Hee-Pyoung Park, M.D.¹

Departments of Anesthesiology and Pain Medicine,¹ Neurosurgery,² Seoul National University Hospital, Seoul, Korea

Objective : The potassium disturbance associated with thiopental continuous infusion in neurosurgical patients is well known. However, the effect of propofol continuous infusion on serum potassium levels has not been investigated extensively.

Methods : We reviewed the medical records of 60 consecutive patients who received coma therapy or deep sedation for intracranial pressure control using either thiopental or propofol between January 2010 and January 2012.

Results : The overall incidence of hypokalemia ($K < 3.5$ mmol/L) was comparable between thiopental and propofol groups (89.2% vs. 82.6%). But, the incidence of moderate to severe hypokalemia ($K < 3.0$ mmol/L) was significantly higher in thiopental group (51.4% vs. 13.0%, $p = 0.003$). The lowest potassium level (2.9 mmol/L vs. 3.2 mmol/L, $p = 0.020$) was lower in thiopental group. The patients in the thiopental group required greater potassium replacement than the propofol group patients (0.08 mmol/kg/h vs. 0.02 mmol/kg/h, $p < 0.001$). On multivariate analysis, thiopental [odds ratio, 95% confidence interval, 7.31 (1.78–27.81); $p = 0.005$] was associated with moderate to severe hypokalemia during continuous infusion. The incidence of rebound hyperkalemia ($K > 5.0$ mmol/L, 32.4% vs. 4.3%, $p = 0.010$) and the peak potassium concentration (4.8 mmol/L vs. 4.2 mmol/L, $p = 0.037$) after the cessation of therapy were higher in thiopental group. On multivariate analysis, thiopental [8.82 (1.00–77.81); $p = 0.049$] and duration of continuous infusion [1.02 (1.00–1.04); $p = 0.016$] were associated with rebound hyperkalemia once therapy was discontinued.

Conclusion : Propofol was less frequently associated with moderate to severe hypokalemia after induction and rebound hyperkalemia following the cessation of continuous infusion than thiopental.

Key Words : Intracranial hypertension · Thiopental · Propofol · Hypokalemia · Hyperkalemia.

INTRODUCTION

Barbiturates are widely used to control refractory intracranial hypertension. They indirectly lower intracranial pressure (ICP) via a coupled reduction in cerebral metabolic rate of oxygen (CMRO₂) and cerebral blood flow. The maximum decrease (roughly 50%) in CMRO₂ occurs when the electroencephalographic readings become isoelectric^{2,17}. Barbiturate therapy, however, is associated with adverse effects, including hypotension and immunosuppression²⁴. Additionally, barbiturates can induce hypokalemia after the induction of coma therapy and cause rebound hyperkalemia after the cessation of therapy^{4,16,19}.

The incidence of hypokalemia after thiopental induction

ranges between 82% and 89.4%^{1,18,19}. A case series reported that 34% of patients had rebound hyperkalemia after stopping thiopental coma therapy¹⁸. There have also been several reports of serious adverse events due to hypokalemia and rebound hyperkalemia^{16,25}. Dyskalemia is life-threatening and a major obstacle to barbiturate coma therapy.

Propofol has been demonstrated to be an effective drug for the regulation of ICP^{10,22}. It decreases ICP in normal subjects and as well as in patients with an elevated ICP¹⁰. It reduces the cerebral metabolic rate by 40% in a dose-dependent fashion and decreases cerebral blood flow by metabolism-flow coupling^{26,27}. Propofol is known to cause hypotension, hypertriglyceridemia, and propofol-related infusion syndrome (PRIS)^{13,20}. Unlike thiopental, however, research has not fully evaluated the effect of

• Received : July 7, 2014 • Revised : October 16, 2014 • Accepted : November 20, 2014

• Address for reprints : Hee-Pyoung Park, M.D.

Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea
Tel : +82-2-2072-2467, Fax : +82-2-747-5639, E-mail : hppark@snu.ac.kr

• This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

propofol continuous infusion on serum potassium levels, especially when used for the regulation of ICP.

The aim of this study was to determine the effect of thiopental and propofol continuous infusion on serum potassium levels when used for ICP control.

MATERIALS AND METHODS

This retrospective study was approved by the Institutional Review Board of Seoul National University Hospital (IRB no. H-1307-047-504) and was in accordance with the Declaration of Helsinki. Patients who were consecutively admitted to the surgical intensive care unit (ICU) to receive coma therapy for the treatment of refractory intracranial hypertension or deep sedation for the prevention of a further increase in ICP from January 2010 to January 2012 were included. Patients without ICP monitoring were excluded from the analysis.

Group assignment

In this study, head elevation, deep sedation, analgesia, use of osmotic agents, and cerebrospinal fluid drainage were used as the first-tier methods to control ICP in patients with elevated ICP. Coma therapy was used when the first-tier therapies failed to reduce ICP to 25 mm Hg.

The patients received one of two regimens for the regulation of ICP, including thiopental ($n=37$) or propofol ($n=23$). In those using thiopental continuous infusions, a loading dose (250 mg) was administered for about 30 min, followed by a continuous infusion of 3–7 mg/kg/h. In those using propofol continuous infusions, a loading dose (100–150 mg) was administered for about 30 min, followed by a continuous infusion of 3–7 mg/kg/h. During both treatments, the cerebral perfusion pressure was maintained at 60–80 mm Hg. Once no further increases in ICP from baseline were detected for 9–18 h in patients with a baseline ICP of <25 mm Hg, in whom deep sedation was needed for ICP control, or if the ICP decreased to ≤ 24 mm Hg and the decrease in ICP was maintained for 24–36 h in patients with refractory intracranial hypertension, both treatments were slowly weaned over 3–12 h.

Definition

Hypokalemia (defined as a serum potassium level <3.5 mmol/L) was managed by potassium replacement (target serum potassium >3.0 mmol/L), while hyperkalemia (defined as a serum potassium level >5.0 mmol/L) was managed with conservative methods such as sodium bicarbonate, insulin, and diuretics. Mild hypokalemia was defined as a serum potassium level of 3.0–3.5 mmol/L. Moderate hypokalemia was defined as a serum potassium level of 2.5–3.0 mmol/L and severe hypokalemia was defined as a level less than 2.5 mmol/L. Hypothermia was defined as a core temperature <35°C. Refractory intracranial hypertension was defined as ICP >25 mm Hg despite the use of first-tier therapies for ICP control.

Measurement

In all patients, serum potassium was measured before therapy. Serum potassium was measured with various intervals (3–8 h) during and after therapy. The same protocol was applied to both groups. The primary outcome in this study was the incidence of hypokalemia during thiopental or propofol continuous infusion. The secondary outcome was the incidence of hyperkalemia after the cessation of thiopental or propofol therapy.

Data collection

Electronic medical records were used to extract and analyze the following parameters: patient's age, sex, past medical history, duration and dose of both therapies, serum potassium level, ICP, Glasgow Coma Scale score prior to therapy, acute physiology and chronic health evaluation II (APACHE II) score, light reflex prior to therapy, the length of ICU stay, ICU mortality, and duration of mechanical ventilation. Variables that possibly contributed to dyskalemia, including urine output, body temperature, vasopressors, inotropes, insulin, mannitol, diuretics, and transfusion, were also extracted and analyzed.

Statistical analyses

Statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). All numerical data are summarized as the mean (standard deviation) or median (interquartile range). Categorical data were compared using the chi-square or Fisher's exact test, if appropriate. Student's t-test was used to compare continuous data. To determine risk factors for hypokalemia and rebound hyperkalemia, univariate analyses were performed and only variables with $p < 0.2$ were entered into the binary logistic analysis with a forward stepwise condition. All tests were two-tailed; $p < 0.05$ was considered statistically significant.

RESULTS

Seventy-one patients were admitted to the surgical ICU during the study period for coma therapy to control refractory intracranial hypertension or for deep sedation to prevent a further increase in ICP. A total of 11 patients without ICP monitoring were excluded; thus, 60 patients were included in this study. Thiopental was used in 37 patients and propofol was used in 23 patients.

There were no statistically significant differences between the two patient groups with respect to age, sex, weight, APACHE II score, neurologic status before therapy, ICP before therapy, and the number of patients having refractory intracranial hypertension (Table 1). A total of 23 (62.2%) patients in the thiopental group had a vascular problem and 15 (65.2%) patients in the propofol group had a tumor.

Changes in serum potassium during and after thiopental or propofol continuous infusion

The overall changes in serum potassium level during thiopental or propofol continuous infusion are shown in Fig. 1. The ini-

Table 1. Characteristics of patients

	Thiopental (n=37)	Propofol (n=23)	p value
Age [yr, mean (range)]	54 (19–82)	51 (19–82)	0.378
Sex (M)	20 (54.1%)	13 (56.5%)	0.852
Weight (kg)	60.9 (1.7)	61.9 (2.2)	0.712
Type of injury (n)			0.001
Trauma	7 (18.9%)	3 (13.0%)	
Tumor	7 (18.9%)	15 (65.2%)	
Vascular	23 (62.2%)	5 (21.7%)	
APACHE II score	23.2±5.2	22.6±5.9	0.683
Craniectomy (n)	13 (35.1%)	10 (43.5%)	0.590
Decompressive lobectomy (n)	2 (5.4%)	1 (4.3%)	>0.999
GCS before therapy [median (IQR)]	3 (3–4)	3 (3–3)	0.014
No light reflex (n)	10 (27.0%)	6 (26.1%)	>0.999
ICP before therapy (mm Hg)	21.7 (15.4)	19.6 (21.5)	0.665
Refractory intracranial hypertension (n)	11 (29.7%)	4 (17.4%)	0.443

Data are presented as number (proportion) or mean (standard deviation) or median (IQR). IQR : interquartile range, APACHE : acute physiology and chronic health evaluation, GCS : Glasgow Coma Scale, ICP : intracranial pressure

tial serum potassium level prior to therapy (3.9 ± 0.6 mmol/L vs. 3.9 ± 0.5 mmol/L, $p=0.800$), total dose administered (5.3 ± 1.5 mg/kg/h vs. 5.3 ± 1.8 mg/kg/h), and therapy duration (60.2 ± 46.3 h vs. 44.1 ± 32.3 h, $p=0.150$) were comparable between thiopental and propofol group. A total of 11 patients had initial serum potassium level less than 3.5 mmol/L (8 in thiopental group vs. 3 in propofol group, $p=0.506$). The incidence of hypokalemia following the induction of therapy was not significantly differed in the thiopental group and propofol group (Table 2). Meanwhile, the incidence of moderate to severe hypokalemia following the induction of therapy was significantly higher in the thiopental group than in the propofol group (51.4% vs. 13.0%, $p=0.003$). The average lowest serum potassium level was lower in the thiopental group than in the propofol group (2.9 ± 0.6 mmol/L vs. 3.2 ± 0.4 mmol/L, $p=0.020$). Also, the average lowest potassium level in patients showing hypokalemia was lower in the thiopental group than in the propofol group ($p=0.009$). The time to the lowest serum potassium concentration was 21.7 ± 13.4 h in thiopental group and 15.2 ± 12.9 h in propofol group. The patients in the thiopental group required greater potassium replacement than the propofol group patients ($p<0.001$).

When therapy was discontinued, the serum potassium levels were 3.5 ± 0.8 mmol/L in the thiopental group and 3.6 ± 0.5 mmol/L in the propofol group (Fig. 2). After continuous infusion was stopped, twelve patients in the thiopental group and one patient in propofol group experienced rebound hyperkalemia ($p=0.010$) (Table 2). Two patients in the thiopental group suffered from ventricular fibrillation (potassium level 8.4 mmol/L) and non-sustained ventricular tachycardia (potassium level 7.4 mmol/L) due to hyperkalemia. The average peak serum potassium level was higher in the thiopental group than in the propofol group (4.8 ± 1.1 mmol/L vs. 4.2 ± 1.1 mmol/L, $p=0.038$). But, the average peak serum potassium level in patients showing hyperkalemia was comparable in both groups. The time to the peak serum potassium concentration was 39.3 ± 24.8 h in thiopental group.




Fig. 1. Mean (standard deviation) serum potassium against time after induction of thiopental or propofol continuous infusion.

Clinical outcomes

Clinical outcomes such as ICU mortality, duration of the ICU stay, and the duration of mechanical ventilation were similar in both groups (Table 3).

Factors associated with hypokalemia or hyperkalemia

Based on a univariate analysis, only urine output [odds ratio, 95% confidence interval, 2.31 (1.06–5.02); $p=0.035$] was associated with hypokalemia during continuous infusion. Thiopental and refractory intracranial hypertension were associated with moderate to severe hypokalemia during continuous infusion in univariate analysis (Table 4). Only thiopental [odds ratio, 95% confidence interval, 7.04 (1.78–27.81); $p=0.005$] was predictive of moderate to severe hypokalemia in binary logistic regression analysis after adjusting for the type of injury, refractory intracranial hypertension, beta agonist, hypothermia. A univariate analysis for rebound hyperkalemia development after stopping continuous infusion is shown in Table 5. According to a binary

Table 2. Serum potassium change during and after thiopental or propofol continuous infusion

	Thiopental (n=37)	Propofol (n=23)	p value
During therapy			
Baseline serum potassium (mmol/L)	3.9 (0.6)	3.9 (0.5)	0.800
Hypokalemia (K<3.5 mmol/L, n)	33 (89.2%)	19 (82.6%)	0.468
Severity (n)			
Mild (3.0≤K<3.5 mmol/L)	14 (37.8%)	16 (69.6%)	0.034
Moderate (2.5≤K<3.0 mmol/L)	11 (29.7%)	2 (8.7%)	0.105
Severe (K<2.5 mmol/L)	8 (21.6%)	1 (4.3%)	0.134
Onset (h)	13.3 (11.2)	15.2 (12.9)	0.583
Lowest level of potassium (mmol/L)	2.8 (0.5)	3.1 (0.4)	0.009
Total potassium replaced (mEq/kg/h)	0.08 (0.04)	0.02 (0.01)	<0.001
After therapy			
Serum potassium when therapy ceased (mmol/L)	3.5 (0.8)	3.6 (0.5)	0.878
Hyperkalemia (K>5.0 mmol/L, n)	12 (32.4%)	1 (4.3%)	0.011
Severity (n)			
Mild (5.0<K≤6.0 mmol/L)	7 (19.9%)	0 (0%)	0.037
Moderate (6.0<K≤8.0 mmol/L)	4 (10.8%)	1 (4.3%)	0.640
Severe (K>8.0 mmol/L)	1 (2.7%)	0 (0%)	>0.999
Onset (h)	26.0 (27.3)	6	0.497
Highest level of potassium (mmol/L)	6.1 (1.1)	6.2	0.907

Data are presented as number (proportion) or mean (standard deviation)




Fig. 2. Mean (standard deviation) serum potassium against time after cessation of thiopental or propofol continuous infusion.

logistic regression analysis, thiopental [8.82 (1.00–77.81); *p*=0.049] and duration of continuous infusion [1.02 (1.00–1.04); *p*=0.016] were associated with rebound hyperkalemia after adjusting for the type of injury, the amount of potassium replaced during the therapy, beta agonist, mannitol, hypothermia.

DISCUSSION

The present study demonstrates that the incidence of hypokalemia was similar in patients receiving thiopental continuous infusion and in patients receiving propofol continuous infusion. However, the incidence of moderate to severe hypokalemia and rebound hyperkalemia were significantly higher in the thiopental group patients. Only thiopental was associated with moderate to severe hypokalemia and rebound hyperkalemia.

In a recent study, the incidence of hypokalemia was 7.5% in patients admitted to an ICU after brain surgery⁵⁾, whereas the incidence of hypokalemia was 80–90% in patients receiving thiopental coma therapy^{19,24)}. In the present study, hypokalemia developed in 89.2% of patients receiving thiopental therapy which was comparable with what has been previously reported. Interestingly, this study showed similar incidence of hypokalemia in thiopental and propofol-infused patients. However, the incidence of moderate to severe hypokalemia was lower in propofol-infused patients than in thiopental-infused patients.

Propofol has been demonstrated to be an effective drug for the regulation of ICP^{10,22)}. It has a short elimination half-life of <1 h and permits frequent and rapid titration. Also, propofol offers faster, more predictable awakenings, and earlier extubation than thiopental or other sedative agents^{7,9)}. Thus, it may be a useful

Table 3. Clinical outcomes of patients receiving thiopental or propofol continuous infusion for intracranial pressure regulation

	Thiopental (n=37)	Propofol (n=23)	<i>p</i> value
Mechanical ventilation duration (d)	12.2 (14.5)	10.1 (20.1)	0.634
Tracheostomy (n)	14 (37.8%)	4 (17.4%)	0.093
ICU mortality (n)	11 (29.7%)	4 (17.4%)	0.283
Duration of ICU stay [d, median (IQR)]	10.4 (6.7–22.9)	8.7 (4.9–12.8)	0.345

Data are presented as number (proportion) or mean (standard deviation) or median (IQR). IQR : interquartile range, ICU : intensive care unit

Table 4. Comparison of variables associated with moderate to severe hypokalemia during thiopental or propofol continuous infusion

	Moderate to severe hypokalemia		Univariate analysis		
	Yes (n=22)	No (n=38)	OR	95% CI	<i>p</i> value
Drug (n)					
Thiopental	19 (86.4%)	18 (47.4%)	7.04	1.78–27.81	0.005
Propofol	3 (13.6%)	20 (52.6%)			
Type of injury (n)					0.080
Trauma	4 (18.2%)	6 (15.8%)			
Tumor	4 (18.2%)	18 (47.4%)	0.33	0.06–1.76	0.196
Vascular	14 (63.6%)	14 (36.8%)	1.50	0.35–6.50	0.588
Renal disease (n)	2 (9.1%)	1 (2.6%)	0.27	0.02–3.17	0.999
GCS before therapy	3.6 (1.2)	3.4 (1.1)	0.83	0.52–1.32	0.421
ICP before therapy (mm Hg)	23.9 (14.1)	19.2 (19.7)	1.01	0.99–1.05	0.340
Refractory intracranial hypertension (n)	9 (40.9%)	6 (15.8%)	3.69	1.09–12.48	0.035
K level before therapy (mEq)	3.9 (0.6)	3.9 (0.5)	1.14	0.41–3.14	0.800
RBC transfusion (n)	8 (36.4%)	12 (31.6%)	0.81	0.27–2.44	0.705
Urine output (mL/kg/h)	4.6 (1.9)	4.3 (2.0)	1.09	0.83–1.42	0.535
Beta agonist (n)	16 (72.7%)	20 (52.6%)	2.40	0.77–7.46	0.130
Insulin (n)	1 (4.5%)	5 (13.2%)	0.31	0.03–2.88	0.306
Mannitol (n)	10 (45.5%)	15 (39.5%)	1.28	0.44–3.70	0.651
Hypothermia (n)	16 (72.7%)	20 (52.6%)	0.42	0.13–1.30	0.130

Data are presented as number (proportion) or mean (standard deviation). OR : odds ratio, CI : confidence interval, GCS : Glasgow Coma Scale, ICP : intracranial pressure, RBC : red blood cell

Table 5. Comparison of variables associated with hyperkalemia development after cessation of thiopental or propofol continuous infusion

	Hyperkalemia		Univariate analysis		
	Yes (n=13)	No (n=47)	OR	95% CI	<i>p</i> value
Drug (n)					
Thiopental	12 (92.3%)	25 (53.2%)	10.56	1.27–87.88	0.029
Propofol	1 (7.7%)	22 (46.8%)			
Type of injury (n)					0.109
Trauma	3 (23.1%)	7 (14.9%)			
Tumor	1 (7.7%)	21 (44.7%)	0.91	0.19–4.34	0.900
Vascular	9 (69.2%)	19 (40.4%)	0.10	0.01–0.87	0.037
Duration of therapy (h)	86.8 (64.2)	45.0 (28.2)	1.02	1.01–1.04	0.005
Renal disease (n)	1 (7.7%)	2 (4.3%)	0.53	0.05–6.39	0.620
Refractory intracranial hypertension (n)	4 (30.8%)	11 (23.4%)	1.46	0.37–5.65	0.589
K level after stopping the therapy (mmol)	3.5 (1.2)	3.6 (0.5)	0.80	0.32–2.00	0.633
K replace during the therapy (mmol/kg/h)	0.07 (0.03)	0.05 (0.05)	2.57	0.07–9.41	0.114
RBC transfusion (n)	4 (30.8%)	16 (34.0%)	1.16	0.31–4.36	0.825
Urine output (mL/kg/h)	3.8 (1.2)	4.5 (2.1)	0.79	0.54–1.16	0.226
Beta agonist (n)	10 (76.9%)	26 (55.3%)	2.69	0.66–11.06	0.169
Insulin (n)	1 (7.7%)	5 (10.6%)	0.70	0.07–6.58	0.755
Mannitol (n)	3 (23.1%)	22 (46.8%)	0.34	0.08–1.40	0.135
Hypothermia (n)	10 (76.9%)	26 (55.3%)	0.37	0.09–1.53	0.169

Data are presented as number (proportion) or mean (standard deviation). OR : odds ratio, CI : confidence interval, RBC : red blood cell

agent for serial neurological examinations in patients with intracranial hypertension. However, the effect of propofol administration on serum potassium levels has not been widely researched, and results are inconsistent. For example, a previous study reported that the serum potassium level fell by 0.04 mmol/L at 5 min after induction with a propofol bolus injection (2.5 mg/kg), but recovered to the pre-induction level within 10 min¹⁵. In contrast, a previous case report showed that a sudden cardiac arrest due to hyperkalemia occurred after propofol single administration¹⁴. Hyperkalemia has been reported as one of clinical manifestations in PRIS patients^{12,28}. PRIS is commonly associated with rhabdomyolysis, and hyperkalemia may have been due to rhabdomyolysis¹². Propofol can decrease beta-adrenoceptor responsiveness²⁹. Therefore, it may block the effect of beta agonists on the intracellular potassium shift. In this study, when propofol was continuously administered for ICP control, hypokalemia was common but the severity was low. We think that other factors rather than propofol caused hypokalemia in propofol continuous infusion group.

There are several possible causes of hypokalemia in neurosurgical patients. First, it is well known that hypokalemia is related to the sympathetic stress response and catecholamine surge in patients with a brain injury^{3,21,23}. This study also showed that refractory intracranial hypertension was associated with moderate to severe hypokalemia in univariate analysis, although it was not an independent factor on binary logistic analysis. Second, hypokalemia can be induced by urinary potassium loss due to mannitol, diuretics or central diabetes insipidus. Our results also showed that urine output during continuous therapy was associated with hypokalemia. Urinary potassium loss and its combination with thiopental infusion can result in more severe hypokalemia. Third, vasopressor therapy, an insulin infusion, and hypothermia can also cause hypokalemia. But, these confounding variables were not associated with hypokalemia in this study.

In the present study, patients receiving thiopental had greater potassium supplementation than those receiving propofol during the infusion therapies. However, the lowest serum potassium level was still significantly lower in patients receiving thiopental and the incidence of moderate to severe hypokalemia was significantly higher in this group. Such finding confirms the association between thiopental and hypokalemia. There are several mechanisms that may explain the hypokalemia development in patients receiving thiopental continuous infusion. First, thiopental inhibits the voltage-dependent potassium current via sodium/potassium ATPase activity and induces the intracellular sequestration of potassium⁸. Second, thiopental inhibits phosphofruktokinase and reduces the intracellular production of pyruvate and lactate, thereby increasing the intracellular pH and inducing an extracellular to intracellular potassium shift⁶.

The potassium disturbance associated with thiopental follows a relatively consistent biphasic pattern consisting of hypokalemia after induction and hyperkalemia after the cessation of

therapy^{4,19}. In the previous studies, rebound hyperkalemia occurred within 6 h with sudden cessation, but occurred 31 h after cessation with gradual weaning of over 12–24 h^{4,19}. It is believed that the intracellular accumulation of potassium during thiopental therapy causes rebound hyperkalemia after the cessation of therapy¹¹. Our study showed that the incidence of rebound hyperkalemia was significantly higher in thiopental-infused patients than in propofol-infused patients. Thiopental and the duration of therapy were significant predictors of rebound hyperkalemia after the cessation of therapy.

Dyskalemia associated with barbiturates can be life-threatening^{4,16,18}. Both hypokalemia and hyperkalemia are potentially fatal. In this study, one patient in the thiopental group suffered from ventricular fibrillation and another patient suffered from non-sustained ventricular tachycardia caused by rebound hyperkalemia. When thiopental is used to control ICP, clinicians should be aware of dyskalemia associated with barbiturate therapy, and serum potassium levels should be closely monitored.

There were several limitations to this study. Since this study was performed retrospectively, data collection was a limitation. The sample size was small. The type of surgery was also heterogeneous. But, our results showed that the type of surgery was not associated with hypokalemia development on the binary logistic analysis. In this study, we focused on serum potassium disturbances during and after the infusion of thiopental or propofol instead of clinical outcomes, because patients with refractory intracranial hypertension as well as patients with a baseline ICP of <25 mm Hg were included in the inclusion criteria.

CONCLUSION

When continuous infusion was used to control intracranial pressure, propofol was less frequently associated with moderate to severe hypokalemia after induction and rebound hyperkalemia after cessation of therapy than thiopental. Whenever thiopental is used to control intracranial hypertension, serum potassium levels should be closely monitored with at least 6-h intervals.

References

1. An HS, Cho BM, Kang JH, Kim MK, Oh SM, Park SH : Efficacy of low dose barbiturate coma therapy for the patients with intractable intracranial hypertension using the bispectral index monitoring. *J Korean Neurosurg Soc* 47 : 252-257, 2010
2. Astrup J, Rosenørn J, Cold GE, Bendtsen A, Møller Sørensen P : Minimum cerebral blood flow and metabolism during craniotomy. Effect of thiopental loading. *Acta Anaesthesiol Scand* 28 : 478-481, 1984
3. Beal AL, Scheltema KE, Beilman GJ, Deuser WE : Hypokalemia following trauma. *Shock* 18 : 107-110, 2002
4. Cairns CJ, Thomas B, Fletcher S, Parr MJ, Finfer SR : Life-threatening hyperkalaemia following therapeutic barbiturate coma. *Intensive Care Med* 28 : 1357-1360, 2002
5. Capparelli FJ, Abello M, Patricio Maskin L, Arista E, Hlavnicka A, Diaz MF, et al. : QTc prolongation after brain surgery. *Neurol Res* 35 : 159-162, 2013

6. Carlsson C, Harp JR, Siesjö BK : Metabolic changes in the cerebral cortex of the rat induced by intravenous pentothalsodium. *Acta Anaesthesiol Scand Suppl* 57 : 1-17, 1975
7. Fogarty DJ, McCleane GJ : Propofol and serum potassium. *Anaesthesia* 47 : 63-64, 1992
8. Friederich P, Urban BW : Interaction of intravenous anesthetics with human neuronal potassium currents in relation to clinical concentrations. *Anesthesiology* 91 : 1853-1860, 1999
9. Hall RI, Sandham D, Cardinal P, Tweeddale M, Moher D, Wang X, et al. : Propofol vs midazolam for ICU sedation : a Canadian multicenter randomized trial. *Chest* 119 : 1151-1159, 2001
10. Hartung HJ : [Intracranial pressure in patients with craniocerebral trauma after administration of propofol and thiopental]. *Anaesthesist* 36 : 285-287, 1987
11. Jung JY, Lee C, Ro H, Kim HS, Joo KW, Kim Y, et al. : Sequential occurrence of life-threatening hypokalemia and rebound hyperkalemia associated with barbiturate coma therapy. *Clin Nephrol* 71 : 333-337, 2009
12. Kam PC, Cardone D : Propofol infusion syndrome. *Anaesthesia* 62 : 690-701, 2007
13. Kelly DF, Goodale DB, Williams J, Herr DL, Chappell ET, Rosner MJ, et al. : Propofol in the treatment of moderate and severe head injury : a randomized, prospective double-blinded pilot trial. *J Neurosurg* 90 : 1042-1052, 1999
14. Lee JH, Ko YS, Shin HJ, Yi JH, Han SW, Kim HJ : Is There a Relationship between Hyperkalemia and Propofol? *Electrolyte Blood Press* 9 : 27-31, 2011
15. Lee JI, Kim YZ, Kim JS, Choi YC, Kim KH : Clinical comparison between barbiturate and propofol coma therapy in the patients with severe traumatic brain injury. *J Korean Neurotraumatol Soc* 4 : 24-30, 2008
16. Machata AM, Gonano C, Birsan T, Zimpfer M, Spiss CK : Rare but dangerous adverse effects of propofol and thiopental in intensive care. *J Trauma* 58 : 643-645, 2005
17. Michenfelder JD : The interdependency of cerebral functional and metabolic effects following massive doses of thiopental in the dog. *Anesthesiology* 41 : 231-236, 1974
18. Neil MJ, Dale MC : Hypokalaemia with severe rebound hyperkalaemia after therapeutic barbiturate coma. *Anesth Analg* 108 : 1867-1868, 2009
19. Ng SY, Chin KJ, Kwek TK : Dyskalaemia associated with thiopentone barbiturate coma for refractory intracranial hypertension : a case series. *Intensive Care Med* 37 : 1285-1289, 2011
20. Otterspoor LC, Kalkman CJ, Cremer OL : Update on the propofol infusion syndrome in ICU management of patients with head injury. *Curr Opin Anaesthesiol* 21 : 544-551, 2008
21. Pomeranz S, Constantini S, Rappaport ZH : Hypokalaemia in severe head trauma. *Acta Neurochir (Wien)* 97 : 62-66, 1989
22. Ravussin P, Guinard JP, Ralley F, Thorin D : Effect of propofol on cerebrospinal fluid pressure and cerebral perfusion pressure in patients undergoing craniotomy. *Anaesthesia* 43 Suppl : 37-41, 1988
23. Schaefer M, Link J, Hannemann L, Rudolph KH : Excessive hypokalemia and hyperkalemia following head injury. *Intensive Care Med* 21 : 235-237, 1995
24. Schalén W, Messeter K, Nordström CH : Complications and side effects during thiopentone therapy in patients with severe head injuries. *Acta Anaesthesiol Scand* 36 : 369-377, 1992
25. Shin IW, Sohn JT, Choi JY, Lee HK, Lee CH, Chung YK : Cardiac arrest due to Severe hypokalemia during barbiturate coma therapy in a patient with severe acute head injury : a case report. *Korean J Anesthesiol* 50 : S71-S73, 2006
26. Stephan H, Sonntag H, Schenk HD, Kohlhausen S : [Effect of Disopri- van (propofol) on the circulation and oxygen consumption of the brain and CO₂ reactivity of brain vessels in the human]. *Anaesthesist* 36 : 60-65, 1987
27. Van Hemelrijck J, Fitch W, Mattheussen M, Van Aken H, Plets C, Lauwers T : Effect of propofol on cerebral circulation and autoregulation in the baboon. *Anesth Analg* 71 : 49-54, 1990
28. Vernooy K, Delhaas T, Cremer OL, Di Diego JM, Oliva A, Timmermans C, et al. : Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. *Heart Rhythm* 3 : 131-137, 2006
29. Zhou W, Fontenot HJ, Wang SN, Kennedy RH : Propofol-induced alterations in myocardial beta-adrenoceptor binding and responsiveness. *Anesth Analg* 89 : 604-648, 1999